EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients

Belaynew W Taye iD, Patricia C Valery iD, Simone I Strasser iD, Martin Weltman iD, Alex J Thompson iD, Miriam T Levy iD, Barbara Leggett, Amany Zekry, Y Julian Rong iD, Marie Sinclair iD, Jacob George iD, William Sievert und 6 weitere

Journal of Viral Hepatitis · 2026-08 · 33 (8)

DOI: 10.1111/jvh.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 24.07.2026. Verfasst von Belaynew W Taye und 17 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, University of Western Australia, Perth, Australia and C…. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Transients and Migrants. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Commonwealth of Australia, Department of Health, Gastroenterological Society of Australia, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The burden of hepatitis C virus (HCV) infection often falls disproportionately on migrant populations within high‐income countries. Differences in health literacy, language, comorbidities, and HCV genotype may influence HCV natural history. 3537 persons including 652 migrants treated for HCV infection with direct‐acting antiviral (DAA) (2016–2021) were analysed. We describe the epidemiology of HCV in migrant people compared to Australian‐born individuals and examine rates of sustained viral response (SVR), advanced liver fibrosis, cirrhosis, and all‐cause mortality. Multivariable logistic and Cox regression analyses examined differences by migrant status. At enrolment, Australian‐born patients were younger (mean 51.5 vs. 54.2 years; p < 0.001) and more likely to report injection drug use ( p = 0.011), risky alcohol use ( p < 0.001), or opioid replacement therapy ( p < 0.001). Among migrants, diabetes (13.9% vs. 10.3%; p = 0.008), hepatitis B virus (HBV) exposure (43.3% vs. 29.7%; p < 0.001), active HBV infection (3.1% vs. 1.6%; p = 0.033), and genotypes 4, 5, and 6 (18.3% vs. 6.6%; p < 0.001) was more common. Overall SVR rates were comparable ( p = 0.69), but SVR rates among migrants with cirrhosis were lower (88.2% vs. 95.2%; p = 0.002). Advanced fibrosis (24.5%), cirrhosis (35.0%), and five‐year survival did not differ by migrant status (all p > 0.05). In migrants, genotype 3 was associated with more advanced liver fibrosis (adj‐OR = 1.70, 95% CI 1.40–2.06) and cirrhosis (adj‐OR = 1.74, 95% CI 1.48–2.04; p < 0.001), relative to Australian‐born patients. Genotypes 2, 4 and 6 HCV were not associated with liver fibrosis and cirrhosis (all p > 0.05). In conclusion, migrants experienced equivalent SVR and rates of liver fibrosis and cirrhosis, and have equivalent or better survival compared to Australian‐born patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsTransients and MigrantsHumansFemaleMaleAustraliaMiddle AgedAdultTreatment OutcomeLiver CirrhosisGenotypeHepacivirusSustained Virologic ResponseAged

Stichwörter der Autor:innen

Hepatitis Ccirrhosisdirect‐acting antiviraldirect‐acting antiviralsliver diseaseliver fibrosissurvivalsustained virologic response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, University of Western Australia, Perth, Australia and Curtin School of Population Health, Curtin University, Perth, Australia.
  • QIMR Berghofer Medical Research Institute, and Faculty of Medicine, the University of Queensland, Brisbane, Queensland, Australia.
  • Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia.
  • Hepatology Services, Nepean Hospital, Penrith, New South Wales, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Department of Gastroenterology and Liver, Liverpool Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Belaynew W Taye, Patricia C Valery, Simone I Strasser, Martin Weltman, Alex J Thompson, Miriam T Levy, Y Julian Rong, Marie Sinclair, Jacob George, Edmund Tse, Wendy Cheng, Stuart K Roberts, Paul J Clark

Förderung

  • Commonwealth of Australia, Department of Health
  • Gastroenterological Society of Australia
  • Gilead Sciences
  • Merck
  • AbbVie

Zitieren

APA

Taye, B. W., Valery, P. C., Strasser, S. I., Weltman, M., Thompson, A. J., Levy, M. T., Leggett, B., Zekry, A., Rong, Y. J., Sinclair, M., George, J., Sievert, W., MacQuillan, G., Tse, E., Wade, A., Cheng, W., Roberts, S. K., & Clark, P. J. (2026). Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients. Journal of Viral Hepatitis, 33(8). https://doi.org/10.1111/jvh.70211

Vancouver

Taye BW, Valery PC, Strasser SI, Weltman M, Thompson AJ, Levy MT, et al. Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients. Journal of Viral Hepatitis. 2026;33(8). doi:10.1111/jvh.70211

BibTeX
@article{Taye2026,
  author = {Taye, Belaynew W and Valery, Patricia C and Strasser, Simone I and Weltman, Martin and Thompson, Alex J and Levy, Miriam T and Leggett, Barbara and Zekry, Amany and Rong, Y Julian and Sinclair, Marie and George, Jacob and Sievert, William and MacQuillan, Gerry and Tse, Edmund and Wade, Amanda and Cheng, Wendy and Roberts, Stuart K and Clark, Paul J},
  title = {Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients},
  journal = {Journal of Viral Hepatitis},
  year = {2026},
  volume = {33},
  number = {8},
  doi = {10.1111/jvh.70211}
}
Kostenlos starten →